FDA Approves New Strength Of Lupin’s Suprax Oral Suspension

Lupin Ltd. Feb. 22 announced that its subsidiary, Lupin Pharmaceuticals Inc., has received approval from the Food and Drug Administration for a new strength of the antibiotic Suprax (cefixime) for oral suspension.

The new drug application provides for a new strength, 500 milligrams/5 milliliters, of Suprax for oral suspension for treating otitis media, acute exacerbation of chronic bronchitis, uncomplicated urinary tract infections, uncomplicated gonorrhea, and pharyngitis/tonsillitis, the company said. Suprax already is available as 100 mg/5 mL and 200 mg/5 mL suspensions; 400 mg tablets; and 100 mg and 200 mg chewable tablets.

In June 2012, FDA also approved a ...